[A21-78] Cenobamate (epilepsy) - Benefit assessment according to §35a Social Code Book
Last updated 19.11.2021
Project no.:
A21-78
Commission:
Commission awarded on 31.05.2021 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Head and nerves
Adjunctive treatment of focal-onset seizures with or without secondary generalization in adult patients with epilepsy who have not been adequately controlled despite a history of treatment with at least 2 anti-epileptic medicinal products
Added benefit not proven.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| G21-30 | Cenobamate (epilepsy) - Addendum to Commission A21-78 | Commission completed |
Federal Joint Committee (G-BA)
19-11-2021 A G-BA decision was published.